|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
We hypothesized that cerebrospinal fluid (CSF) biomarkers of amyloid, neurodegeneration, and endothelial dysfunction would differ between older African Americans and Caucasians with normal cognition and cognitive impairment associated with AD.
|
29096697 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
The secondary goal was to determine the neuroimaging variables from MRI, FDG PET and CSF biomarkers that can predict future cognitive decline within each group.
|
29415470 |
2018 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Concentrations of CSF biomarkers, additionally to severity of the cognitive impairment, significantly contribute in predicting specific personality changes.
|
28213293 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated CSF cortisol may also be associated with a more rapid cognitive decline in MCI due to AD.
|
30881301 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
The finding that amnestic MCI based on brief neuropsychological assessment is significantly associated with CSF biomarkers for cognitive decline and Alzheimer's disease is in accordance with longitudinal studies that find memory impairment; both in itself and especially in combination with other cognitive deficit to constitute a risk factor for subsequent cognitive decline and dementia.
|
30614807 |
2019 |
|
Impaired cognition
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We aimed to explore the critical structural alterations in the process of cognitive decline and its relationships with the dopaminergic deficit and the level of related cerebrospinal fluid (CSF) proteins.
|
31278861 |
2020 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taking advantage of repeated amyloid PET and CSF measures, this dynamic view offers new insight into the progression of Alzheimer's disease biomarkers and their relationships with cognitive decline.
|
31350262 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
CSF A<i>β</i>, <i>α</i>-synuclein, and neurogranin concentrations are related to cortical metabolism and cognitive decline.
|
29046879 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> The typical deposition of <sup>18</sup>F-AV1451 tau PET imaging in AD brain was found in amygdala, entorhinal cortex, fusiform and parahippocampus, and these regions were strongly associated with cognitive impairment and CSF biomarkers.
|
31156534 |
2019 |
|
Impaired cognition
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In an asymptomatic at-risk cohort, elevated CSF Aβ (with or without elevated tau) was associated with greater rates of cognitive decline, with the specific pattern of decline varying across cognitive measures.
|
29523644 |
2018 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum and CSF levels of anti-Aβ autoantibodies and CSF biomarkers were evaluated in 68 patients with cognitive impairment, comprising 44 patients with AD, 19 patients with amnestic MCI and five patients with non-Alzheimer's dementia.
|
27330118 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Delirium is a marker of brain vulnerability, associated with increasing age, pre-existing cognitive impairment and, recently, cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease.
|
30862889 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
CSF flux is involved in the pathophysiology of neurodegenerative diseases and cognitive impairment after traumatic brain injury, all hallmarked by the accumulation of cellular metabolic waste.
|
28137972 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most use CSF biomarkers to diagnose atypical (84%) and early-onset cases of cognitive impairment (71%) and for the differential diagnosis of other dementias (69%).
|
28826189 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, in case of co-existence of cognitive impairment and depression in the elderly, we propose CSF AD biomarkers analysis to early differentiate LLD from AD and properly target the patient's therapeutic strategy and clinical follow-up.
|
29527163 |
2018 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients completed neuropsychological tests, core CSF AD biomarkers assessment (Aβ<sub>1-42</sub>, total tau, and phosphorylated tau), and follow-up for a mean of 3 years to verify cognitive decline.
|
30317034 |
2019 |
|
Impaired cognition
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We included 768 patients (194 with subjective cognitive decline (SCD), 127 mild cognitive impairment (MCI), 309 Alzheimer's dementia (AD), and 138 non-AD) who were categorized as concordant-negative (n = 315, 41%), discordant (n = 97, 13%), or concordant-positive (n = 356, 46%) based on CSF and PET results.
|
31511058 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
3446 individuals (1154 AD cases and 2292 controls) were included in the analyses of AD risk, 1400 individuals (cognitively normal = 747, AD = 653) in the CSF biomarker analyses, and 861 individuals in the analyses of cognitive decline.
|
30792413 |
2019 |
|
Impaired cognition
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We included 63 individuals with subjective cognitive decline (age 64 ± 8, MMSE 29 ± 1), with amyloid status (positron emission tomography [PET] scans n = 59, or Aβ<sub>1-42</sub> cerebrospinal fluid [CSF] n = 4).
|
31075283 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of 4 subgroups (Cognitive impairment ± and Biomarkers ±) showed significant associations of dementia and CSF biomarker concentrations to mortality after an AHF.
|
31508810 |
2020 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
These disruptions did not correlate with cognitive impairment or CSF biomarkers.
|
28702344 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
The relationship of contactin-2 with cognitive decline (Mini-Mental State Examination (MMSE)) and other CSF biomarkers reflecting AD pathology were analyzed.
|
29859129 |
2018 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, we tried to identify a cerebrospinal fluid (CSF) biomarker correlated with the degree and rate of cognitive decline in progressive MS patients.
|
31802039 |
2020 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate, if a potentially reduced CSF flow due to the giant arachnoid cyst contributed to the early manifestation of AD, we reviewed 15 case series of subjects with frontotemporal arachnoid cysts and cognitive decline.
|
31488095 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expert commentary: A large number of pilot studies have been reported but so far there is a lack of replicated findings and to date no CSF biomarker discovered in proteomic studies has reached the clinic to aid in the diagnostic work-up of patients with cognitive impairment.
|
28942688 |
2017 |